Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Breast Cancer

Free Subscription 01.09.2025 5 Ann Surg Oncol 6 Anticancer Res 1 BMC Cancer 4 BMJ 1 Br J Cancer 7 Breast Cancer 3 Breast Cancer (Auckl) 1 Breast Cancer (Dove Med Press) 3 Breast Cancer Res 8 Breast Cancer Res Treat 1 Cancer Epidemiol Biomarkers Prev 3 Clin Breast Cancer 1 Clin Cancer Res 1 Exp Cell Res 1 Int J Cancer 1 J Biol Chem 3 J Clin Oncol 1 J Natl Cancer Inst 2 J Surg Oncol 2 NPJ Breast Cancer 2 Oncogene 1 PLoS One 1 Proc Natl Acad Sci U S A 1 Radiol Artif Intell

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Surg Oncol

1. VAN HASSEL J, Dimitroff K, Yau C, Mukhtar R, et al
   ASO Visual Abstract: Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial.
   Ann Surg Oncol. 2025 Aug 29. doi: 10.1245/s10434-025-18131.
   PubMed        
   
   
2. CHU C, Goldman J, Joung H, Go S, et al
   Breast Cancer Incidence Among Patients Undergoing Chest Masculinization Surgery: A Scoping Review.
   Ann Surg Oncol. 2025 Aug 28. doi: 10.1245/s10434-025-18156.
   PubMed         Abstract available
   
   
3. VARMAN PM, Conner A, Bennett WC, Taft D, et al
   ASO Visual Abstract: Impact of Second Opinions on Time to Treatment of Breast Cancer.
   Ann Surg Oncol. 2025 Aug 27. doi: 10.1245/s10434-025-18180.
   PubMed        
   
   
4. YI M, Chavez-MacGregor M, Smith BD, Mitchell MP, et al
   ASO Visual Abstract: Comparing Survival Differences Between Patients Undergoing Breast-Conserving Therapy Versus Total Mastectomy as a First Treatment for Early Stage Breast Cancer.
   Ann Surg Oncol. 2025 Aug 27. doi: 10.1245/s10434-025-18217.
   PubMed        
   
   
5. REASON EH, Thomas SM, Chanenchuk T, Botty van den Bruele A, et al
   ASO Visual Abstract: Neoadjuvant Chemotherapy is Not Associated with Improved Overall Survival in Metaplastic Breast Cancer Regardless of Tumor Subtype.
   Ann Surg Oncol. 2025 Aug 26. doi: 10.1245/s10434-025-18181.
   PubMed        
   
   

   
   Anticancer Res

6. SAWA A, Sato R, Matsuo T, Okazaki M, et al
   Paclitaxel-induced Peripheral Neuropathy and Quality of Life: Sub-analysis of the MICHEL Study.
   Anticancer Res. 2025;45:3827-3833.
   PubMed         Abstract available
   
   
7. CIPOLLA C, Gebbia V, DI Stefano V, Messina C, et al
   Opsoclonus-myoclonus Syndrome in a Female Breast Cancer Patient: A Case Report and Literature Review.
   Anticancer Res. 2025;45:4037-4045.
   PubMed         Abstract available
   
   
8. WAGNER JK, Leinhos F, Kunze CA, Bick U, et al
   Prevalence of Incidental Breast Cancer and Precursor Lesions in Carriers of Pathogenic Germline Variants Undergoing Risk-Reducing Mastectomy.
   Anticancer Res. 2025;45:3749-3760.
   PubMed         Abstract available
   
   
9. AQUINO IG, DE Almeida PC, Rangel-Coelho JP, DE Castro Raucci LMS, et al
   Influence of Caffeic Acid Phenethyl Ester on Osteoblastic Cell Behavior in Coculture With Breast Adenocarcinoma Cells.
   Anticancer Res. 2025;45:3719-3726.
   PubMed         Abstract available
   
   
10. ESKELINEN M, Koskela R, Selander T, Kaarniranta K, et al
    Psychological Stress Versus Outcome in Patients With Breast Disease and Breast Cancer: A Prospective 25-year Follow-up Study in Patients With Breast Cancer Symptoms.
    Anticancer Res. 2025;45:3817-3826.
    PubMed         Abstract available
    
    
11. LYRONIS G, Efraimidou E, Zachou ME, Kaprana A, et al
    Impact of Fentanyl and Remifentanil on Immune Response in Breast Cancer Patients Post-surgery.
    Anticancer Res. 2025;45:3761-3771.
    PubMed         Abstract available
    
    

    
    BMC Cancer

12. KURANT DE, Groha S, Ding Y, German C, et al
    Association between polygenic risk and survival in breast cancer patients.
    BMC Cancer. 2025;25:1393.
    PubMed        
    
    

    
    BMJ

13. MACKENZIE M, Stobart H, Dodwell D, Taylor C, et al
    Patients need information on the risk of second cancer after early breast cancer.
    BMJ. 2025;390:r1584.
    PubMed        
    
    
14. BOWIE K
    Risk of second cancer after early breast cancer is low, study finds.
    BMJ. 2025;390:r1819.
    PubMed        
    
    
15. SANCHEZ MJ, Petrova D
    Second primary cancers in breast cancer survivors.
    BMJ. 2025;390:r1798.
    PubMed        
    
    
16. MCGALE P, Dodwell D, Challenger A, Cutter D, et al
    Second cancers in 475 000 women with early invasive breast cancer diagnosed in England during 1993-2016: population based observational cohort study.
    BMJ. 2025;390:e083975.
    PubMed         Abstract available
    
    

    
    Br J Cancer

17. WU Y, Zhou L, Zhao J, Peng Y, et al
    Relation knowledge distillation 3D-ResNet-based deep learning for breast cancer molecular subtypes prediction on ultrasound videos: a multicenter study.
    Br J Cancer. 2025 Aug 26. doi: 10.1038/s41416-025-03146.
    PubMed         Abstract available
    
    

    
    Breast Cancer

18. CHANG CC, Huang PW, Lin JC, Tsai JT, et al
    Risk factors for early-onset radiodermatitis in patients with locally advanced breast cancer: a comparative analysis of volumetric modulated arc therapy and intensity-modulated radiotherapy.
    Breast Cancer. 2025 Aug 27. doi: 10.1007/s12282-025-01762.
    PubMed         Abstract available
    
    
19. KAWAMURA C, Bhaskaran K, Konishi T, Sagara Y, et al
    Risk of endometrial cancer among breast cancer survivors in Japan: a matched cohort study.
    Breast Cancer. 2025 Aug 27. doi: 10.1007/s12282-025-01769.
    PubMed         Abstract available
    
    
20. CHAROENYOTHAKUN A, Shotelersuk K, Nantavithya C, Saksornchai K, et al
    The impact of adjuvant radiotherapy on borderline and malignant phyllodes tumors of the breast.
    Breast Cancer. 2025;32:1006-1012.
    PubMed         Abstract available
    
    
21. CERRAI S, Lachi A, Franchini M, Pieroni S, et al
    Alcohol consumption and breast lesions: targets for risk-based screening in high-risk Italian women.
    Breast Cancer. 2025;32:970-978.
    PubMed         Abstract available
    
    
22. FANNING JE, Givant M, Chen A, Thomson S, et al
    Major anatomic variations of the lateral upper arm lymphatic pathway in a healthy female population.
    Breast Cancer. 2025;32:1125-1131.
    PubMed         Abstract available
    
    
23. YAMAGUCHI T, Koyama Y, Inoue K, Ban K, et al
    Development of a deep learning-based automated diagnostic system (DLADS) for classifying mammographic lesions - a first large-scale multi-institutional clinical trial in Japan.
    Breast Cancer. 2025;32:1115-1124.
    PubMed         Abstract available
    
    
24. IMAI A, Tsunashima R, Hidaka Y, Kitano S, et al
    Validation of the predictive ability for recurrence and the clinical utility of the 95-gene classifier (95GC) through an integrated analysis of five studies.
    Breast Cancer. 2025;32:1075-1087.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Auckl)

25. LIN CW, Chang KM, Ku WH, Kao KJ, et al
    Tumor Immune Response as a Biomarker for Metastasis-Free Survival of Breast Cancer and Immune Checkpoint Inhibition Therapy: A Retrospective Cohort Study.
    Breast Cancer (Auckl). 2025;19:11782234251363665.
    PubMed         Abstract available
    
    
26. SUGHAYER M, Al-Jussani G, Salem A, Mullahwaish Y, et al
    Human Epidermal Growth Factor Receptor 2-Low Breast Cancer: Prevalence Rate and Scoring Concordance Among Pathologists.
    Breast Cancer (Auckl). 2025;19:11782234251363664.
    PubMed         Abstract available
    
    
27. KOTOWICZ B, Fuksiewicz M, Jodkiewicz M, Makowka A, et al
    Evaluation of the Prognostic Value of Obesity, Vitamin D Concentrations, and Systemic Inflammatory Response Indexes (SIRI, SII, PIV) in Patients With Breast Cancer Scheduled for Neoadjuvant Treatment.
    Breast Cancer (Auckl). 2025;19:11782234251369463.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

28. ZHOU S, Jiang M, Liu J, Zhang M, et al
    Safety Profile and Predictors of Adverse Events of Incadronate Disodium in Treating Breast Cancer Patients with Bone Metastases: A Retrospective Study.
    Breast Cancer (Dove Med Press). 2025;17:727-739.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

29. CHEN CH, Chen IC, Hsu CL, Lu TP, et al
    Characterization of the tumor immune microenvironment in pregnancy-associated breast cancer through multiplex immunohistochemistry and transcriptome analyses.
    Breast Cancer Res. 2025;27:154.
    PubMed         Abstract available
    
    
30. ZHANG F, de Bock GH, Landman GW, Zhang Q, et al
    Longitudinal changes in metabolism-related metrics and breast cancer risk: a general population study.
    Breast Cancer Res. 2025;27:155.
    PubMed         Abstract available
    
    
31. TRINH L, Parks J, McDonald T, Roth A, et al
    Pre-diagnostic serum metabolome and breast cancer risk: a nested case-control study.
    Breast Cancer Res. 2025;27:156.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

32. SANLI AN, Turan B, Tekcan Sanli DE, Karaca I, et al
    Neoadjuvant response stratification based on complete, partial, and no response in HR-positive/HER2-positive breast cancer.
    Breast Cancer Res Treat. 2025 Aug 28. doi: 10.1007/s10549-025-07812.
    PubMed         Abstract available
    
    
33. WEI J, Aller A, Zhu S, Habel LA, et al
    Beyond the 5-year mark: adherence to and continuation of extended adjuvant endocrine therapy in non-metastatic breast cancer patients.
    Breast Cancer Res Treat. 2025 Aug 27. doi: 10.1007/s10549-025-07811.
    PubMed         Abstract available
    
    
34. LIU Z, Liu Z, Wang M, Liu Y, et al
    Transcriptomic and microenvironment characteristics of triple-negative breast cancer under three different neoadjuvant treatment regimens.
    Breast Cancer Res Treat. 2025 Aug 27. doi: 10.1007/s10549-025-07810.
    PubMed         Abstract available
    
    
35. SHI L, Kolor K, Chen Z, Moonesinghe R, et al
    BRCA testing utilization among commercially insured women with breast or ovarian cancer.
    Breast Cancer Res Treat. 2025;213:291-298.
    PubMed         Abstract available
    
    
36. STRINGER-REASOR EM, Saha P, Kocherginsky M, Lastra R, et al
    Carboplatin, gemcitabine, and mifepristone for advanced breast and recurrent/persistent epithelial ovarian cancer.
    Breast Cancer Res Treat. 2025;213:347-354.
    PubMed         Abstract available
    
    
37. CHOI S, Park B, Lee EG, Lee S, et al
    Prediction of upstaging in DCIS: the dominant role of pathological over imaging risk factors.
    Breast Cancer Res Treat. 2025;213:325-334.
    PubMed         Abstract available
    
    
38. MAMTANI A, Sevilimedu V, Barrio AV, Morrow M, et al
    Axillary dissection is avoidable in most cT1N0 triple-negative & HER2+ breast cancers treated with upfront surgery.
    Breast Cancer Res Treat. 2025;213:355-363.
    PubMed         Abstract available
    
    
39. KOVACS A, Klint L, Linderholm B, Parris TZ, et al
    Changes in HER2low and HER2-ultralow status in 47 advanced breast carcinoma core biopsies, matching surgical specimens, and their distant metastases assessed by conventional light microscopy, digital pathology, and artificial intelligence.
    Breast Cancer Res Treat. 2025;213:397-408.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

40. ABDOLLAHPOUR I, Darouei B, Amani-Beni R, Yazdi M, et al
    Lifetime Sunlight Exposure and Risk of Breast Cancer: A Population-based incident Case-Control Study.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

41. LUBAS MJ, Hasler J, Fredette J, Sandoval-Leon A, et al
    The Role of Adjuvant Radiation Therapy in Treating Older Breast Cancer Patients With Low Adherence to Endocrine Therapy.
    Clin Breast Cancer. 2025 Jul 30:S1526-8209(25)00225.
    PubMed         Abstract available
    
    
42. HERMANS KEPE, Geurts SME, Van den Berkmortel F, Tol J, et al
    Receptor Discordance During the Treatment Course of Patients With Metastatic Breast Cancer: Results From the SONABRE Registry.
    Clin Breast Cancer. 2025 Jul 30:S1526-8209(25)00217.
    PubMed         Abstract available
    
    
43. GARCIA-TEJEDOR A, Julia C, Ciria J, Guevara-Peralta R, et al
    Prognostic Outcomes by Axillary Approach in Lobular and Ductal Breast Cancer With Sentinel Node Macrometastases: A Retrospective Cohort Study.
    Clin Breast Cancer. 2025 Aug 5:S1526-8209(25)00219.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

44. ROYCE M, Shah M, Zhang L, Cheng J, et al
    FDA Approval Summary: Datopotamab deruxtecan-dlnk for treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer.
    Clin Cancer Res. 2025 Aug 27:10.1158/1078-0432.CCR-25-1388.
    PubMed         Abstract available
    
    

    
    Exp Cell Res

45. ZHANG M, Chen H, Zhang L, Yuan A, et al
    Cryptotanshinone instigates ferroptosis to inhibit the development of tamoxifen-resistant breast cancer via the AMPK induced BECN1-SLC7A11 complex axis.
    Exp Cell Res. 2025;451:114726.
    PubMed         Abstract available
    
    

    
    Int J Cancer

46. MARKIEWICZ A
    A mass cytometry-based lens on DNA damage repair in circulating tumor cells from breast cancer patients.
    Int J Cancer. 2025 Aug 29. doi: 10.1002/ijc.70105.
    PubMed        
    
    

    
    J Biol Chem

47. YOSHIOKA Y, Nosaka C, Ohishi T, Nakajima M, et al
    Loss of Angulin-1/LSR promotes vasculogenic mimicry and epithelial-mesenchymal transition in breast cancer.
    J Biol Chem. 2025 Aug 27:110635. doi: 10.1016/j.jbc.2025.110635.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

48. GOETZ MP, Choong GM, Hoskin TL, Boughey JC, et al
    Reply to: "Rethinking Treatment Priorities in Estrogen Receptor-Low Breast Cancer" and "CDK4/6 Inhibitors in Estrogen Receptor-Low Breast Cancer".
    J Clin Oncol. 2025 Aug 28:JCO2501688. doi: 10.1200/JCO-25-01688.
    PubMed        
    
    
49. FREEMAN JQ, Nanda R, Howard FM
    Rethinking Treatment Priorities in Estrogen Receptor-Low Breast Cancer.
    J Clin Oncol. 2025 Aug 28:JCO2501176. doi: 10.1200/JCO-25-01176.
    PubMed        
    
    
50. ERGUN Y
    CDK4/6 Inhibitors in Estrogen Receptor-Low Breast Cancer.
    J Clin Oncol. 2025 Aug 28:JCO2500836. doi: 10.1200/JCO-25-00836.
    PubMed        
    
    

    
    J Natl Cancer Inst

51. CARBONE A, Oliva M, Puntoni M, Guerrieri-Gonzaga A, et al
    Effect of low-dose tamoxifen on benign gynecological and breast conditions in a phase III trial in non-invasive breast cancer.
    J Natl Cancer Inst. 2025 Aug 28:djaf250. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

52. GABAY AJ, Chen J, Stern CS, Gibbons C, et al
    Predicting Breast Reconstruction Readmission, Reoperation, and Prolonged Length of Stay: A Machine Learning Approach.
    J Surg Oncol. 2025;132:345-353.
    PubMed         Abstract available
    
    
53. LEVY J, Amakiri U, Shammas RL, Graziano FD, et al
    Longitudinal Modeling in Surgical Oncology Research: A Primer Examining Patient-Reported Outcomes.
    J Surg Oncol. 2025;132:294-307.
    PubMed         Abstract available
    
    

    
    NPJ Breast Cancer

54. OZMEN F, Ozmen TY, Ors A, Janghorban M, et al
    Single-cell RNA sequencing reveals different cellular states in malignant cells and the tumor microenvironment in primary and metastatic ER-positive breast cancer.
    NPJ Breast Cancer. 2025;11:95.
    PubMed         Abstract available
    
    
55. BRANTLEY KD, Kirkner GJ, Hughes ME, Varella L, et al
    The association between young age at metastatic breast cancer diagnosis and overall survival in the EMBRACE study.
    NPJ Breast Cancer. 2025;11:96.
    PubMed         Abstract available
    
    

    
    Oncogene

56. BARNIEH FM, Morton J, Olanrewaju O, El-Khamisy SF, et al
    Decoding the adaptive survival mechanisms of breast cancer dormancy.
    Oncogene. 2025 Aug 27. doi: 10.1038/s41388-025-03529.
    PubMed         Abstract available
    
    
57. CHEN X, Ma C, Li Y, Liang Y, et al
    Correction: COL5A1 promotes triple-negative breast cancer progression by activating tumor cell-macrophage crosstalk.
    Oncogene. 2025 Aug 28. doi: 10.1038/s41388-025-03554.
    PubMed        
    
    

    
    PLoS One

58. SALAR-ANDREU C, Montero-Navarro S, Lozano-Rubio A, Del Rio-Medina S, et al
    Effectiveness of radiofrequency and exercise-based rehabilitation on symptoms associated with pelvic floor dysfunction in breast cancer patients: A study protocol.
    PLoS One. 2025;20:e0330156.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

59. KARNER ER, Wang M, Goel HL, Mercurio AM, et al
    GATA3 promotes ferroptosis resistance by repressing integrin beta1 signaling.
    Proc Natl Acad Sci U S A. 2025;122:e2427304122.
    PubMed         Abstract available
    
    

    
    Radiol Artif Intell

60. SCHNITZLER T
    Quantitative Pharmacokinetic Mapping with AI: Toward More Generalizable Response Prediction in Breast Cancer MRI.
    Radiol Artif Intell. 2025;7:e250550.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.